Hydrolysis of imipenem, meropenem, ceftazidime, and cefepime by multiresistant nosocomial strains of Sphingobacterium multivorum

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 2, 1997, Pages 178-180

  Blahova J ^a   Kralikova K ^a   Krcmery Sr V ^a   Kubonova K ^b  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b Derer 's University Hospital Slovakia   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; IMIPENEM; MEROPENEM;

ARTICLE; DRUG HYDROLYSIS; FLAVOBACTERIUM; HOSPITAL INFECTION; NONHUMAN; PRIORITY JOURNAL;

CEFTAZIDIME; CEPHALOSPORINS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FLAVOBACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; HYDROLYSIS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 0030981389     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01709484     Document Type: Article

References (15)

1. Shewan JM, McMeekin TA: Taxonomy (and ecology) of Flavobacterium and related genera. Annual Review of Microbiology 1983, 37: 233-252.
2. Sader HS, Jones RN, Pfaller MA: Relapse of catheter-related Flavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis. Clinical Infectious Diseases 1995, 21: 997-1000.
3. Hsueh PR, Wu JJ, Hsiue TR, Hsieh WC: Bacteremic necrotizing fasciitis due to Flavobacterium odoratum. Clinical Infectious Diseases 1995, 21: 1337-1338.
4. Boliver R, Abramovits W: Cutaneous infection caused by Flavobacterium meningosepticum. Journal of Infectious Diseases 1989, 159: 150-151.
5. Blahová J, Hupková M, Krǒméry, Kuboňová K: Resistance to and hydrolysis of imipenem in nosocomial strains of Flavobacterium meningosepticum. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13: 833.
6. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A4. NCCLS, Villanova, PA, 1990.
7. Neu HC: Antibiotic bacterial resistance. In: Lorian V (ed): Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, 1986, p. 762-765.
8. Inoue E, Mitsuhashi S: In vitro antibacterial activity and β-lactamase stability of SY 5555, a new oral penem antibiotic. Antimicrobial Agents and Chemotherapy 1994, 38: 1974-1979.
9. Livermore D: Carbapenemases: the next generation of β-lactamases? American Society for Microbiology News 1993, 59: 129-135.
10. Payne DJ: Metallo-β-lactamases - a new therapeutic challenge. Journal of Medical Microbiology 1993, 39: 93-99.
11. Philippon A, Arlet G, Lagrange PH: Origin and impact of plasmid-mediated extended-spectrum β-lactamases. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13: 17-29.
12. Blasquez J, Baquero MR, Canton R, Alos I, Baquero F: Characterisation of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 1993, 37: 2059-2063.
13. Sirot D, Chanal C, Henquell C, Labia R, Sirot J, Cluzel R: Clinical isolates of Escherichia coli producing multiple TEM-mutants resistant to β-lactam inhibitors. Journal of Antimicrobial Chemotherapy 1994, 33: 1117-1126.
14. Livermore DM, Yuan M: Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. Journal of Antimicrobial Chemotherapy 1996, 38: 409-424.
15. Livermore D: Carbapenemases: the next generation of β-lactamases? American Society for Microbiology News 1993, 59: 129-135.